BIOACTIVITY ASSAY DEVELOPMENT CONSULTING SERVICES

Investigators

Abstract

This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management. The Assay Development Consultant provides technical guidance to the following programs: • Assay Development consulting to support the NIH Helping to End Addiction Long-term [HEAL] Initiative HEAL initiative aims to optimize non-addictive Therapies [Small Molecules and Biologics] to treat Pain. • Assay Development consulting to support The Blueprint Neurotherapeutics Program [BPN] drug development programs. • Other NIH neuroscience-focused drug discovery and development programs. The NIH Blueprint for Neuroscience Research, a consortium of 8 NIH Institutes and Centers that support neuroscience research, established the Blueprint Neurotherapeutics Network (BPN) as a pipeline between the typical endpoint of NIH-funded research and the beginning of industry drug development. The BPN provides neuroscience researchers with funding and access to a full range of industry-style drug development services and expertise. The program is intended for projects requiring medicinal chemistry optimization and contract research organization (CRO) support through Phase I clinical testing. The HEAL program supports preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate promising small molecule and biologic hits/leads towards clinical trials. The HEAL program will provide neuroscience researchers with funding and access to a full range of industry-style drug development services and expertise. The program is intended for projects requiring medicinal chemistry optimization and contract research organization (CRO) support through Phase I clinical testing.